Table 1. Baseline demographics of study participants.
| Characteristic | Controls n = 464 |
Cases n = 99 |
All N = 563 |
|---|---|---|---|
| Male, n (%) | 408 (88) | 78 (79) | 486 (86) |
| Female, n (%) | 56 (12) | 21 (21) | 77 (14) |
| Age in years, median (IQR) | 38.1 (31.8 – 44.7) | 37.2 (29.7 – 46.2) | 37.9 (31.5 – 45.4) |
| Self-identified race/ethnicity, n (%) | |||
| White | 283 (61) | 49 (49.5) | 332 (59) |
| Black | 144 (31) | 39 (39.5) | 183 (32.5) |
| Hispanic | 18 (4) | 6 (6) | 24 (4) |
| Asian | 5 (1) | - | 5 (1) |
| Not reported | 14 (3) | 5 (5) | 19 (3.5) |
| Concomitant NRTIs, n (%) | |||
| Tenofovir | 52 (53) | 243 (52) | 295 (52) |
| Emtricitabine | 50 (51) | 233 (50) | 283 (50) |
| Lamivudine | 40 (40) | 204 (44) | 244 (43) |
| Zidovudine | 33 (33) | 158 (34) | 191 (34) |
| Abacavir | 5 (5) | 32 (7) | 37 (7) |
| Stavudine | 2 (2) | 22 (5) | 24 (4) |
| Didanosine | 0 (0) | 7 (2) | 7 (1) |